Contineum Therapeutics, Inc.
CTNM
$11.43
-$0.10-0.87%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -58.44M | -59.98M | -59.39M | -56.86M | -49.83M |
| Total Depreciation and Amortization | 328.00K | 323.00K | 313.00K | 294.00K | 275.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.85M | 10.38M | 8.96M | 7.87M | 6.30M |
| Change in Net Operating Assets | -10.90M | -6.04M | -2.36M | 2.25M | 3.98M |
| Cash from Operations | -57.17M | -55.31M | -52.47M | -46.44M | -39.28M |
| Capital Expenditure | -496.00K | -231.00K | -355.00K | -339.00K | -414.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 20.00K | 20.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -57.44M | -3.48M | 34.71M | -10.45M | -63.16M |
| Cash from Investing | -57.94M | -3.71M | 34.35M | -10.77M | -63.56M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 113.12M | 112.94M | 20.12M | 946.00K | 108.90M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -325.00K | -256.00K | -256.00K | -176.00K | 140.00K |
| Cash from Financing | 112.79M | 112.69M | 19.86M | 770.00K | 109.04M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.31M | 53.66M | 1.74M | -56.45M | 6.21M |